GlassScriptPhysician profile
Gary R Feldman
NPI 1841220373
$116,420.00
in general payments reported to CMS, 2019-2025
19 companies · $227 in 2025
The $227 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $33K · 2021: $24K · 2022: $771 · 2023: $1,563 · 2024: $1,140 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,299 · Education: $631.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.33 |
| Education | $630.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $42,372.87 | 2019-2021 | |
| Amgen INC. | $41,146.61 | 2019-2025 | Evenity, Prolia, Uplizna |
| United Rheumatology | $29,329.30 | 2019-2021 | |
| Janssen Biotech, INC. | $1,036.85 | 2019-2024 | Tremfya, Simponi Aria |
| Ucb, INC. | $483.09 | 2022-2024 | Bimzelx |
| Abbvie INC. | $463.09 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $358.97 | 2020-2024 | |
| Depuy Synthes Sales INC. | $301.77 | 2019 | |
| Pfizer INC. | $258.62 | 2020-2023 | |
| Genzyme Corporation | $193.41 | 2023 | |
| Johnson & Johnson Health Care Systems INC. | $157.45 | 2019-2022 | |
| Horizon Therapeutics Plc | $80.89 | 2022-2023 | Krystexxa |
| Sanofi-Aventis U.S. LLC | $76.93 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $63.02 | 2019-2022 | |
| Sobi, INC | $39.15 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $22.18 | 2019 | |
| Vertiflex, INC. | $19.13 | 2019 | |
| Merck Sharp & Dohme LLC | $16.67 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Feldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.